By Robert Preidt HealthDay Reporter
MONDAY, Might 16, 2022 (HealthDay Information) — As america mourns a million deaths from COVID-19, a brand new research signifies the grim tally might have been worse. Use of the Pfizer-BioNTech COVID-19 vaccine prevented greater than 110,000 deaths and 690,000 hospitalizations in america in 2021, researchers report.
The vaccine additionally prevented 8.7 million symptomatic circumstances of an infection and saved greater than $30 billion in well being care prices and greater than $40 billion in misplaced productiveness, the research authors famous.
“The analyses present that the Pfizer-BioNTech COVID-19 vaccine contributed substantial public well being impression within the U.S. in 2021, and had a deep impact on the trajectory of the pandemic,” mentioned Manuela Di Fusco, of Pfizer’s well being economics and outcomes analysis crew.
The Pfizer vaccine was the primary COVID-19 shot accessible in america. It was given to almost six in 10 folks nationwide who had been totally vaccinated in 2021, based on the U.S. Facilities for Illness Management and Prevention.
The findings had been revealed on-line Might 15 within the Journal of Medical Economics. All the research authors acquired funding from Pfizer both as workers, consultants or workers of corporations paid by Pfizer.
Regardless of using COVID-19 vaccines, the U.S. loss of life toll throughout the pandemic neared a million final week.
President Joe Biden ordered U.S. flags flown at half-staff Thursday.
“We should stay vigilant in opposition to this pandemic and do the whole lot we will to save lots of as many lives as attainable,” Biden mentioned.
On this research, researchers estimated the impression of the Pfizer vaccine utilizing a mannequin, real-world information and scientific trial information.
The mannequin used information on the variety of folks vaccinated, the effectiveness of the vaccine in varied age teams, and the probabilities of being contaminated, creating signs and being hospitalized.
It additionally included the consequences of long COVID, the variety of working days seemingly misplaced because of short-term sickness and the financial impression of untimely deaths from the illness.
The mannequin didn’t embody the impression of the extra transmissible Omicron variant that grew to become the dominant coronavirus pressure on the finish of the research interval.
The vaccine “was estimated to stop tens of millions of COVID-19 symptomatic circumstances, hundreds of hospitalizations and deaths, and generated billions in societal financial worth within the U.S. in 2021,” Di Fusco mentioned in a journal information launch.
The findings “spotlight the chance to proceed widespread vaccination uptake to stop COVID-19-related illness and generate societal advantages,” she added.
Quite a lot of limitations might have resulted within the numbers within the research being underestimates, based on Di Fusco and colleagues. These embody not factoring within the vaccine’s potential to scale back transmission of the coronavirus, the severity of circumstances and the general impression of lengthy COVID .
The researchers additionally famous that their findings cannot be utilized to different COVID-19 vaccines or teams of individuals not particularly analyzed within the research.
There’s extra on COVID-19 vaccines on the U.S. Facilities for Illness Management and Prevention.
SOURCE: Journal of Medical Economics, information launch, Might 16, 2022